Pharmather is a Canadian life sciences listed company that is developing psychedelics for brain and nervous system disorders.
PharmaTher
From their website: “Pharmather (CSE: PHRM) is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. Pharmather was founded with a focus on repurposing psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system.”
One of their products is an AI tool (panaceAI) to find effective (psychedelic) drugs for rare disorders.
The company also goes by the name ‘Newscope Capital Corporation’.
Revive Therapeutics has recently (December 2020) bought Pharmather’s research into psilocybin.
PharmaTher has raised a total of U$8 million in funding over 1 round. This was a Post-IPO Equity round raised on Sep 24, 2021.
The company is now listed on the CNSX under the ticker PHRM.
Key Staff
- Fabio Chianelli – Chairman & CEO (previously of Revive)
- Carmelo Marrelli – CFO
News
- Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program (press release, December 2020)
- PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Novel Use of Psilocybin to Treat Cancer (press release, November 2020)
- Newscope Capital (d/b/a Pharmather) Announces Listing on the Canadian Securities Exchange (press release, October 2020)
Activities
B2B
B2C
Pharmaceutical
Topics of Interest
Pain
Depression
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease (BioSpace, 23 March 2022)PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch (, 11 November 2021)
PharmaTher announces that it has successfully completed its first research study evaluating MicroDose-MN™, a proprietary microneedle patch for the intradermal delivery of psychedelics, in delivering psilocybin.
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus (, 24 November 2021)
Revive Therapeutics Inc. (OTCMKTS: RVVTF) Signs Psilocybin Research Partnership Agreement With PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) (, 24 November 2021)
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio (, 30 November 2021)
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022 (, 21 December 2021)
PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products (, 23 April 2024)
PharmaTher announces it has entered into an agreement with Alcami Corporation for the clinical and commercial manufacturing of the company’s proprietary ketamine products.